Biocon Ltd. NSE: BIOCON | BSE: 532523

Mid-range Performer

Download real time

372.10 -7.95 (-2.09%)

27.87% Gain from 52W Low

3.5M

NSE+BSE Volume

NSE 07 Jul, 2025 3:31 PM (IST)

Biocon Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Biocon Ltd. from all sources in a single place.

07 Jul 2025, 08:05AM

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

04 Jul 2025

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Publication

03 Jul 2025

372.10

-2.09%

Karnataka CM's remark on Covid vaccines 'factually incorrect': Biocon chief

Business Standard

Biocon founder Kiran Mazumdar-Shaw on Thursday opposed Karnataka Chief Minister Siddaramaiah's remarks linking covid-19 vaccines with a spate of heart attack deaths in the state's Hassan district, saying such claims are "'factually incorrect" and "misleading". Siddaramaiah has suggested that the recent heart attack deaths in Hassan district may be linked to the vaccination drive. He had also claimed the vaccines were 'hastily' approved. In a social media post, Shaw said "covid-19 vaccines developed in India were approved under the Emergency Use Authorisation framework, following rigorous protocols aligned with global standards for safety and efficacy. To suggest that these vaccines were 'hastily' approved is factually incorrect and contributes to public misinformation." "These vaccines have saved millions of lives and, like all vaccines, may cause side effects in a very small number of individuals. It is important to acknowledge the science and data-driven processes behind their...

Number of FII/FPI investors increased from 297 to 305 in Mar 2025 qtr.

03 Jul 2025

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

02 Jul 2025

372.10

-2.09%

Biocon climbs 3% on plans to file approvals for generic weight-loss drug

Business Standard

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of Novo Nordisk A/S's Ozempic and Wegovy

Biocon Ltd. has an average target of 389.25 from 4 brokers.

Biocon aims to lead copycat Wegovy sales in Canada from next year

Business Line | 02 Jul 2025 1 more

30 Jun 2025

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

27 Jun 2025

372.10

-2.09%

Biocon drops plan to launch weight-loss drugs in China, executive says

Business Line

There is ample capacity and players available in China, says Amit Kaptain, head of Biocon's commercial active pharmaceutical ingredients business

Biocon Ltd. is trading above all available SMAs

27 Jun 2025

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

26 Jun 2025

372.10

-2.09%

SAST

Biocon Ltd - 532523 - Closure of Trading Window

BSE India

Closure of Trading Window

26 Jun 2025

372.10

-2.09%

Company Update

Biocon Ltd - 532523 - Disclosure Under Regulation 30 Of The SEBI Listing Regulations

BSE India

Disclosure under Regulation 30 of the SEBI Regulations

Is Biocon Ltd. worth buying?

721 Votes:

Buy 75.03%

Sell 16.23%

Hold 8.74%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >